Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
Sumitomo Dainippon Pharma will make its third attempt for a PIII trial of its atypical antipsychotic lurasidone, sold as Latuda overseas, to obtain data to seek approval in Japan for the treatment of schizophrenia, President Masayo Tada revealed on October…
To read the full story
Related Article
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
BUSINESS
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
- Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan
December 9, 2025
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…